Overview
GDRX market data
Price History
GDRX price chart
Valuation & Profitability
- P/E (TTM)
- 78.00 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.09 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.73 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 2.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.77 – $5.81 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.3B · P/B 1.49 · P/S 1.61.
Company News
UBS Maintains Neutral on GoodRx Holdings, Raises Price Target to $3.75Benzinga · Aug 13, 2026, 9:20 PM
Citigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $5Benzinga · Aug 11, 2026, 8:08 PM
TD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $5Benzinga · Aug 11, 2026, 4:01 PM
GoodRx Holdings Raises FY2026 Sales Guidance from $765.000M-$785.000M to $790.000M-$805.000M vs $775.751M EstBenzinga · Aug 5, 2026, 8:38 PM
GoodRx Holdings Q2 Adj. EPS $0.08, Inline, Sales $200.411M Beat $193.162M EstimateBenzinga · Aug 5, 2026, 8:08 PM
GoodRx Launches Its $14.99 Per Month Subscription Service, GoodRx CompanionBenzinga · May 27, 2026, 1:06 PM
Citigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $4Benzinga · May 14, 2026, 6:57 PM